| 產(chǎn)品編號 | bsm-63048R |
| 英文名稱(chēng) | CDKN2A Recombinant Rabbit mAb |
| 中文名稱(chēng) | 抑癌基因p16重組兔單抗 |
| 別 名 | CDKN2; MTS1; isoforms 1/2/3; Cyclin-dependent kinase 4 inhibitor A; CDK4I; P16INK4; p16INK4a; Multiple tumor suppressor 1; |
| 抗體來(lái)源 | Rabbit |
| 克隆類(lèi)型 | Recombinant |
| 克 隆 號 | 14E19 |
| 交叉反應 | Human |
| 產(chǎn)品應用 | WB=1:500-2000,IHC-P=1:100-500,IHC-F=1:100-500,IF=1:100-500
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 理論分子量 | 17 kDa |
| 檢測分子量 | |
| 細胞定位 | 細胞核 細胞漿 |
| 性 狀 | Liquid |
| 免 疫 原 | A synthesized peptide derived from human CDKN2A: 120-156/156 |
| 亞 型 | IgG |
| 純化方法 | affinity purified by Protein A |
| 緩 沖 液 | 10mM phosphate buffered saline , pH 7.4, 150mM sodium chloride, 0.05% BSA, 0.02% Proclin300 and 50% glycerol. |
| 保存條件 | Shipped at 4℃. Store at -20℃ for one year. Avoid repeated freeze/thaw cycles. |
| 注意事項 | This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. |
| PubMed | PubMed |
| 產(chǎn)品介紹 |
This gene generates several transcript variants which differ in their first exons. At least three alternatively spliced variants encoding distinct proteins have been reported, two of which encode structurally related isoforms known to function as inhibitors of CDK4 kinase. The remaining transcript includes an alternate first exon located 20 Kb upstream of the remainder of the gene; this transcript contains an alternate open reading frame (ARF) that specifies a protein which is structurally unrelated to the products of the other variants. This ARF product functions as a stabilizer of the tumor suppressor protein p53 as it can interact with, and sequester, the E3 ubiquitin-protein ligase MDM2, a protein responsible for the degradation of p53. In spite of the structural and functional differences, the CDK inhibitor isoforms and the ARF product encoded by this gene, through the regulatory roles of CDK4 and p53 in cell cycle G1 progression, share a common functionality in cell cycle G1 control. This gene is frequently mutated or deleted in a wide variety of tumors, and is known to be an important tumor suppressor gene. [provided by RefSeq, Sep 2012] Function: Acts as a negative regulator of the proliferation of normal cells by interacting strongly with CDK4 and CDK6. This inhibits their ability to interact with cyclins D and to phosphorylate the retinoblastoma protein. Subunit: Heterodimer with CDK4 or CDK6. Predominant p16 complexes contained CDK6. Interacts (isoforms 1,2 and 4) with CDK4 (both 'T-172'-phosphorylated and non-phosphorylated forms); the interaction inhibits cyclin D-CDK4 kinase activity. Interacts with ISCO2. Subcellular Location: Cytoplasm. Nucleus. Tissue Specificity: Widely expressed but not detected in brain or skeletal muscle. Isoform 3 is pancreas-specific. Post-translational modifications: Ubiquitinated in normal cells by TRIP12 via the ubiquitin fusion degradation (UFD) pathway, a process that mediates ubiquitination at the N-terminus, regardeless of the absence of lysine residues. Ubiquitination leads to its degradation. In cancer cells, however, TRIP12 is located in a different cell compartment, preventing ubiquitination and degradation. DISEASE: Note=The association between cutaneous and uveal melanomas in some families suggests that mutations in CDKN2A may account for a proportion of uveal melanomas. However, CDKN2A mutations are rarely found in uveal melanoma patients. Defects in CDKN2A are the cause of cutaneous malignant melanoma type 2 (CMM2) [MIM:155601]. Malignant melanoma is a malignant neoplasm of melanocytes, arising de novo or from a pre-existing benign nevus, which occurs most often in the skin but also may involve other sites. Defects in CDKN2A are the cause of familial atypical multiple mole melanoma-pancreatic carcinoma syndrome (FAMMMPC) [MIM:606719]. Defects in CDKN2A are a cause of Li-Fraumeni syndrome (LFS) [MIM:151623]. LFS is a highly penetrant familial cancer phenotype usually associated with inherited mutations in TP53. [DISEASE] Defects in CDKN2A are the cause of melanoma-astrocytoma syndrome (MASTS) [MIM:155755]. The melanoma-astrocytoma syndrome is characterized by a dual predisposition to melanoma and neural system tumors, commonly astrocytoma. Similarity: Belongs to the CDKN2 cyclin-dependent kinase inhibitor family. Contains 4 ANK repeats. SWISS: P42771 Gene ID: 1029 Database links: p16主要功能是通過(guò)抑制CDK4而阻止細胞由G1期進(jìn)入S期，使細胞增殖受到限制。用于各種惡性腫瘤如肺癌、惡黑、乳腺癌的研究。目前的研究細胞周期依賴(lài)激酶抑制p16INK4a蛋白在宮頸上皮內病變(CIN)中作為一個(gè)新標記物. p16INK4a的過(guò)表達與HPV E7區(病毒早期蛋白即病毒致癌基因編碼區)活性有密切相關(guān)性。 p16/CDKN2基因是新近發(fā)現的腫瘤抑制基因，已有研究表明該基因在許多腫瘤出現缺失、突變或重排現象. |
| 產(chǎn)品圖片 |
25 ug total protein per lane of various lysates (see on figure) probed with CDKN2A monoclonal antibody, unconjugated (bsm-63048R) at 1:1000 dilution and 4°C overnight incubation. Followed by conjugated secondary antibody incubation at r.t. for 60 min.
Paraformaldehyde-fixed, paraffin embedded Human Tonsil; Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15 min; The section was incubated with CDKN2A Monoclonal Antibody, Unconjugated (bsm-63048R) at 1:200 overnight at 4°C, followed by conjugation to the bs-0295G-HRP and DAB (C-0010) staining.
Paraformaldehyde-fixed, paraffin embedded Human Ovarian mucinous carcinoma; Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15 min; The section was incubated with CDKN2A Monoclonal Antibody, Unconjugated (bsm-63048R) at 1:200 overnight at 4°C, followed by conjugation to the bs-0295G-HRP and DAB (C-0010) staining.
Paraformaldehyde-fixed, paraffin embedded Human Colon Cancer; Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15 min; The section was incubated with CDKN2A Monoclonal Antibody, Unconjugated (bsm-63048R) at 1:200 overnight at 4°C, followed by conjugation to the bs-0295G-HRP and DAB (C-0010) staining.
Paraformaldehyde-fixed, paraffin embedded Human Cervical Cancer; Antigen retrieval by boiling in sodium citrate buffer (pH6.0) for 15 min; The section was incubated with CDKN2A Monoclonal Antibody, Unconjugated (bsm-63048R) at 1:200 overnight at 4°C, followed by conjugation to the bs-0295G-HRP and DAB (C-0010) staining.
|
